Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Dogecoin Falls More Than 7% In 24 hours

Dogecoin's (CRYPTO: DOGE) price has decreased 7.02% over the past 24 hours to $0.13, continuing its downward trend over the past week of -9.0%, moving from $0.15 to its current price.
byBenzinga Insights
June 14, 2024
1 minute read
Total
0
Shares
0
0
0
0
0
0

Dogecoin’s (CRYPTO: DOGE) price has decreased 7.02% over the past 24 hours to $0.13, continuing its downward trend over the past week of -9.0%, moving from $0.15 to its current price.

The chart below compares the price movement and volatility for Dogecoin over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.

price_chart

The trading volume for the coin has decreased 41.0% over the past week, while the overall circulating supply of the coin has decreased 0.11% to over 144.68 billion. The current market cap ranking for DOGE is #10 at $19.20 billion.

supply_and_vol

Powered by CoinGecko API

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

This Analyst With 83% Accuracy Rate Sees Over 35% Upside In Amazon.com – Here Are 5 Stock Picks For Q3 From Wall Street’s Most Accurate Analysts

By Lisa Levin
October 2, 6:12 AM
The Dow Jones closed lower on Friday following the release of personal consumption expenditures price index. The S&P 500 fell around 4.9% in September and ended the quarter lower by 3.7%. The Dow recorded a 3.5% decline for September and a 2.6% decline for the quarter.

AMAN

Read More

What’s Going On With Revolution Medicines Stock?

By Erica Kollmann
April 10, 12:20 PM
Revolution Medicines announced the publication of a peer-reviewed research paper in "Cancer Discovery" detailing the discovery and preclinical to clinical translation for RMC-6236 on Monday. The company also announced the publication of two peer-reviewed research papers in "Nature" Tuesday. The first paper highlights the discovery and preclinical characterization of RMC-7977, and the second paper highlights the systematic evaluation of RMC-7977 in a wide range of preclinical models of PDAC.

RVMD